Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.

Eric J Small,Kim N Chi,Simon Chowdhury,Katherine B Bevans,Amitabha Bhaumik,Fred Saad,Byung Ha Chung,Lawrence I Karsh,Stéphane Oudard,Peter De Porre,Sabine D Brookman-May,Sharon A McCarthy,Suneel D Mundle,Hirotsugu Uemura,Matthew R Smith,Neeraj Agarwal

European urology oncology（2023）

引用 0|浏览11

暂无评分

摘要

Quality of life is maintained in individuals with advanced prostate cancer who achieve a deep prostate-specific antigen decline at 3 mo of apalutamide plus drugs that lower male sex hormones.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要